Core Insights - IBA announces that a landmark study published in The Lancet recommends proton therapy as the new standard of care for oropharyngeal cancer, providing the highest level of evidence for its benefits over conventional radiotherapy [1][4]. Industry Overview - Oropharyngeal cancer is a significant global health issue, with over 100,000 new cases diagnosed annually. Current treatments often lead to severe side effects, highlighting the need for more effective therapies [2]. Clinical Trial Details - The study involved over 20 institutions and enrolled 440 patients, marking the first level 1 randomized phase 3 trial comparing Intensity-Modulated Proton Therapy (IMPT) with advanced photon therapy (IMRT) [3]. - The trial provides strong evidence for proton therapy's safety and effectiveness, establishing it as a transformative solution for oropharyngeal cancer [3]. Key Findings - The five-year overall survival rate for patients receiving IMPT is 90.9%, compared to 81.0% for those receiving IMRT, indicating a significant improvement in survival [6]. - IMPT also shows a 42% reduction in the hazard of death and significantly lower rates of severe toxicities compared to IMRT [6]. Expert Commentary - Experts emphasize the importance of this study in establishing proton therapy as the standard of care for advanced oropharyngeal cancer, with potential for increased accessibility for patients [4].

Core Insights - IBA reported strong revenue growth and improved profitability in the first half of 2025, driven by effective backlog conversion [2][4] Financial Performance - Total net sales increased by 40% year-over-year to EUR 304.9 million, with IBA Clinical and IBA Technologies growing by 47% and 30% respectively [3][4] - Gross profit rose to EUR 90.0 million, a 27% increase, while gross margin decreased to 29.5% from 32.6% due to a less favorable equipment profitability mix [3][4] - Operating expenses (OPEX) were controlled at EUR 79.4 million, representing 26% of total net sales, leading to a REBITDA of EUR 16.4 million, up 141% from the previous year [3][4] - The company reported a net loss of EUR 2.6 million, an improvement from a loss of EUR 10.3 million in H1 2024, attributed to non-recurring expenses and foreign exchange fluctuations [4] Order Intake and Backlog - Equipment order intake was EUR 107 million, a decrease of 7% compared to H1 2024, with a notable decline in Proton Therapy orders by 35% [5] - The backlog decreased to EUR 1.3 billion, driven by increased backlog conversion, with expectations for H2 order intake to be stronger [5] Strategic Developments - IBA's new CFO, Catherine Vandenborre, started on July 1, 2025, as part of the company's strategic initiatives [5] - The company reaffirmed its 2025 guidance, targeting a Group REBIT of at least EUR 25 million by year-end, supported by positive performance in Proton Therapy [6] Operational Highlights - PanTera began production of Actinium-225 in Belgium to support clinical trials, with a large-scale facility expected to break ground in Q4 2025 [5][6] - The company is implementing a new Enterprise Resource Planning (ERP) system, anticipated to be completed by early 2026 [7]

Company Overview - IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology and a leading supplier of equipment and services in proton therapy, which is the most advanced form of radiation therapy available today [6] - The company is also a key player in industrial sterilization, radiopharmaceuticals, and dosimetry [6] - IBA is based in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people worldwide [6] - The company is listed on the pan-European stock exchange EURONEXT [7] Upcoming Financial Results - IBA will publish its consolidated results for the half year 2025 on Thursday, 28 August 2025 at 7am CEST [2] - A conference call and webcast will be hosted by IBA's management team on the same day at 3pm CEST, which will include a Q&A session [3] - The presentation will be available on IBA's investor relations website shortly before the call [4]

Group Overview - IBA reported a solid start to 2025, driven by strong market momentum in Proton Therapy and positive trends in Dosimetry [4][6] - The company has a backlog of €1.5 billion in IBA Clinical Equipment and Services, with a positive net cash position of €9 million [6] - A share buyback program is ongoing, with 582,849 shares purchased as of May 19, 2025, against a target of 650,000 by year-end [6] Proton Therapy and Dosimetry - There are currently 38 ongoing proton therapy projects, including 8 ProteusPLUS and 30 ProteusONE systems, with 9 installations underway [7] - Strong commercial activity is noted in the Asia-Pacific region, with significant contracts signed in India and Taiwan [7] - The integration of Radcal Corporation is back on track, supporting profitability in Dosimetry [7] Product Innovations - IBA launched the QUASAR GRID system and myQA Blue Phantom, enhancing quality assurance solutions [7] - Two additional sales in Radio Pharma Solutions were activated post-period, including a contract in Taiwan [7] - The company introduced CASSY, a new compact synthesizer aimed at improving efficiency in radiotracers production [7] Financial Outlook - IBA maintains its one-year guidance for 2025, expecting a REBIT of at least €25 million, supported by positive performance in Proton Therapy [9] - The mid-term outlook (2024-2028) indicates confidence in sustained profitability while monitoring macroeconomic conditions [10] - Revenue is projected to grow at a normalized frontloaded rate of 5-7% CAGR, with OPEX expected to be up to 30% of sales per annum [14]

Core Insights - IBA has launched CASSY, a compact synthesizer aimed at revolutionizing radiopharmaceutical production processes, particularly for radiometals and radiotracers [1][5]. Group 1: Product Features - CASSY enhances efficiency in radiopharmaceutical production through seamless integration into laboratory workflows, user-friendly interfaces, and versatility for purification and radiolabelling [2]. - The compact design allows stacking of up to six units in a single standard hot cell, optimizing space and increasing production potential, making it suitable for laboratories with limited space [3]. - CASSY is adaptable for a wide range of radioisotopes, catering to diverse research and clinical needs, and is positioned for future innovations like radiotheranostics [3]. Group 2: Components and Technology - CASSY utilizes specific cassettes developed by Fluidomica, which include all necessary components for radioisotope and radiopharmaceutical manufacturing processes [4]. - The cassettes are designed for single use, ensuring efficiency and reliability in production [4]. Group 3: Company Commitment and Leadership - Charles Kumps, President of IBA RadioPharma Solutions, emphasized that CASSY represents a significant advancement in theranostic innovation, enhancing the quality and reliability of radiopharmaceutical manufacturing [5]. - IBA continues to lead the radiopharmaceutical industry through its commitment to innovation and improving healthcare outcomes globally [5]. Group 4: Company Overview - IBA is recognized as the world leader in particle accelerator technology and is a major supplier in proton therapy, industrial sterilization, and dosimetry, employing approximately 2,100 people worldwide [7]. - The company is listed on the EURONEXT stock exchange and is a certified B Corporation, meeting high standards of social and environmental performance [8].

Core Insights - IBA has launched the QUASAR GRID Advantage Image Distortion Analysis System, enhancing quality assurance in MR-guided radiation therapy and MR simulation planning [1][2]. Company Overview - IBA (Ion Beam Applications S.A.) is a leader in particle accelerator technology and a major provider of dosimetry and quality assurance solutions, employing approximately 2,100 people globally [6][7]. - The company is recognized for its advanced proton therapy equipment and services, which are considered the most sophisticated form of radiation therapy available today [6]. Product Features - The GRID Advantage system is designed for facilities needing precise MR distortion analysis for stereotactic planning, ensuring geometric fidelity in MR images [2][3]. - It offers automated analysis through user-friendly software and includes versatile multi-use solutions with various frame adapters or frameless options [2]. Industry Context - The use of MR in radiation therapy is increasing due to its superior soft tissue contrast without ionizing radiation, making precise imaging critical for effective tumor targeting and protection of healthy tissue [3]. - The introduction of robust QA tools like GRID Advantage is essential to maintain image fidelity and enhance clinical confidence in treatment accuracy [3][4]. Expert Commentary - Industry experts highlight that the GRID Advantage represents a significant advancement in quality assurance for Gamma Knife radiosurgery, emphasizing the importance of geometric distortion QA in radiation therapy workflows [4].

Company Overview - IBA (Ion Beam Applications) is the world's leading provider of proton therapy solutions for cancer treatment, specializing in particle accelerator technology and advanced radiation therapy [11] - The company is based in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people globally [11] - IBA is listed on the pan-European stock exchange EURONEXT [12] Shareholding Notification - FMR LLC issued a transparency notification regarding a change in voting rights, indicating that Fidelity Management & Research Company LLC crossed downwards the 1% threshold on April 3, 2025 [2][10] - Following the transaction, Fidelity Management & Research Company LLC holds 397,873 voting rights, representing 0.98% of the total voting rights [5] - The total voting rights held by all entities under FMR LLC amount to 579,650, which is 1.43% of the total [5][6] Controlled Undertakings - The chain of controlled undertakings includes FIAM LLC, which is controlled by FIAM Holdings LLC, and FMR Investment Management (UK) Limited, controlled by Fidelity Management & Research Company LLC [8] - FMR LLC is the parent company and is not a controlled undertaking [8] Investment Management - The holdings attributed to the entities mentioned arise from various collective investment undertakings managed by FIAM LLC, FMR Investment Management (UK) Limited, and Fidelity Management & Research Company LLC [9] - These entities act as discretionary investment managers and exercise voting rights at their discretion in the absence of specific instructions [9]